newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022

Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter WALTHAM, Mass., Nov.